TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
NAMS

NewAmsterdam Pharma Company N.V.

Healthcare · Biotechnology

22.60$ -0.7% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

NewAmsterdam Pharma Company N.V. (NAMS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 23 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement NAMS
Line item 2020 2021 2022 2023 2024 2025
0.0 0.0 103 14 46 23
– 0.0 0.1 0.0 0.1 0.1
– 0.0 103 14 46 22
4.9 29 87 159 151 142
1.7 4.7 20 38 70 106
6.6 35 106 197 222 248
-6.6 -35 -3.6 -183 -176 -226
0.3 0.4 0.3 6.8 0.0 –
-7.0 -42 -23 -177 -242 -204
0.3 0.2 71 0.0 0.0 –
-7.0 -42 -23 -177 -242 -204
-6.6 -41 -22 -177 -241 -242

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?